Here's What You May Have Missed About NextGen Healthcare (NXGN)

NextGen Healthcare logged a 2.0% change during today's evening session, and is now trading at a price of $18.31 per share. On average, analysts give it a target price of $20.74.

NextGen Healthcare, Inc. provides healthcare technology solutions in the United States. The small-cap company is based in the United States.

What to Consider if You Are Thinking of Buying NextGen Healthcare:

  • NextGen Healthcare has moved 4.0% over the last year.

  • NXGN has a forward P/E ratio of 13.8 based on its EPS guidance of 1.33.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of -31.5%.

  • The company has a price to earnings growth (PEG) ratio of 5.27.

  • Its Price to Book (P/B) ratio is 2.99

NextGen Healthcare Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2022-05-18 53,545 -2,582 56,127 -45.12
2021-05-27 98,518 -3,761 102,279 9.92
2020-06-01 85,601 -7,449 93,050 67.88
2019-05-29 50,475 -4,952 55,427 -35.84
2018-05-25 76,586 -9,801 86,387 -29.63
2017-05-19 110,592 -12,165 122,757

NextGen Healthcare's free cash flows have a decent average of $86.0 Million over the last 6 years, but they are highly variable since their coefficient of variability is 483644863.4%. The compounded average growth rate over this period is 0.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS